3-三氟甲基苄硫醇 | 25697-55-6

• 物质功能分类: 化学试剂 - 有机试剂 - 硫醇盐
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-三氟甲基苄硫醇
• 中文别名: 3-(三氟甲基)苯甲硫醇；3-(三氟甲基)苄基硫醇
• 英文名称: m-trifluoromethylbenzyl mercaptan
• 英文别名: (3-(trifluoromethyl)phenyl)methanethiol；3-(trifluoromethyl)benzyl thiol；[3-(Trifluoromethyl)phenyl]methanethiol
• CAS: 25697-55-6
• 化学式: C₈H₇F₃S
• mdl: MFCD00042435
• 分子量: 192.205
• InChiKey: CQIQWIMXCPTQPJ-UHFFFAOYSA-N

物化性质

• 沸点：
  79 °C
• 密度：
  1.253±0.06 g/cm3(Predicted)
• 闪点：
  75-77°C/5mm
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解。避免接触氧化物和空气。

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xn
• 安全说明：
  S23,S36/37
• 危险类别码：
  R20/21/22
• 危险品运输编号：
  2810
• 海关编码：
  2930909090
• 包装等级：
  III
• 危险类别：
  6.1

SDS

Name:	[3-(Trifluoromethyl)phenyl]methanethiol tech Material Safety Data Sheet
Synonym:
CAS:	25697-55-6

Section 1 - Chemical Product MSDS Name:[3-(Trifluoromethyl)phenyl]methanethiol tech Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
25697-55-6	[3-(Trifluoromethyl)phenyl]methanethio		unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.Moisture sensitive.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Combustible liquid.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Keep away from sources of ignition. Store in a cool, dry place.
Store in a tightly closed container. Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 25697-55-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless - pale yellow
Odor: stench
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 75 - 77 deg C @5mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H7F3S
Molecular Weight: 192

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Oxidizing agents, bases, amines.
Hazardous Decomposition Products:
Carbon monoxide, oxides of sulfur, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 25697-55-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
[3-(Trifluoromethyl)phenyl]methanethiol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
IMO
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
RID/ADR
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 25697-55-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 25697-55-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 25697-55-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-三氟甲基苄硫醇 在 dipotassium peroxodisulfate 、 tetrakis(pyridine)silver(II) peroxodisulfate 、 氧气 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 23.0 ℃ 、101.33 kPa 条件下， 以75%的产率得到3-三氟甲基苯甲醛
  参考文献：
  名称：

  可见光介导的银（II）配合物实现的苄基硫醇的氧化CS键裂解。

  摘要：

  使用单线态氧进行C–S键的氧化裂解反应具有挑战性，因为其性质不可控。我们已经开发了一种使用银（II）-配体配合物进行单线态氧介导的选择性CS键断裂反应的新方法。可见光诱导的银催化作用使苄基硫醇能够被控制地氧化裂解，从而提供羰基化合物，例如醛或酮，它们是重要的合成组分。

  DOI：

  10.1021/acs.orglett.0c01399
• 作为产物：
  描述：

  1-氯甲基-3-三氟甲基苯 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 3.33h， 生成 3-三氟甲基苄硫醇
  参考文献：
  名称：

  反式（+-）-N-甲基-2-（3-吡啶基）-2-四氢硫代吡喃碳硫酰胺1-氧化物（RP 49356）及其类似物的合成和生物活性：一类新型的钾通道开放剂。

  摘要：

  报道了反式-（+-）-N-甲基-2-（3-吡啶基）-2-四氢硫代吡喃氨基甲磺酰胺+++ e 1-氧化物（8a，RP 49356）和类似物的合成和生物活性。这些化合物构成K（+）通道开放剂的新结构类。讨论了吡啶基，硫代酰胺和硫杂环上的变化对体外K（+）通道开放反应性的影响。为了活性，优选3-吡啶基或3-喹啉基，小的N-烷基硫代酰胺官能团和氧化亚砜环，其中亚砜与硫代酰胺具有反式关系。选择的化合物在降压麻醉的大鼠中静脉内测试降压作用，其活性反映了其体外K（+）通道的开放活性。

  DOI：

  10.1021/jm00098a004

文献信息

• Inhibitors of c-Jun N-terminal kinases
  申请人：Liu Gang

  公开号：US20060173050A1

  公开（公告）日：2006-08-03

  The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.

  本发明涉及作为c-jun N-末端激酶1、2或3（JNK1、JNK2或JNK3）抑制剂的化合物，包含这些化合物的组合物以及这些化合物在预防或治疗由JNK1、JNK2和JNK3激活调控的疾病中的用途。
• [EN] MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS DE HSD17B13 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：REGENERON PHARMA

  公开号：WO2021003295A1

  公开（公告）日：2021-01-07

  The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.

  本公开涉及能够调节羟基类固醇17-β脱氢酶（HSD17B）家族成员蛋白的化合物和药物组合物，包括抑制HSD17B家族成员蛋白，例如HSD17B13。本公开还涉及使用此处披露的化合物和药物组合物治疗肝脏疾病、障碍或状况的方法，其中HSD17B家族成员蛋白发挥作用。
• Conversion of thiols into sulfonyl halogenides under aerobic and metal-free conditions
  作者：Marjan Jereb、Luka Hribernik

  DOI：10.1039/c7gc00556c

  日期：——

  a redox-catalytic cycle. Sulfonyl chlorides and bromides were isolated without extraction and “filtered” over a short pad of silica gel; the use of solvents was greatly reduced in comparison with traditional isolation and purification. A “one-pot” protocol for the conversion of thiol into sulfonamide is also demonstrated. Scale-up experiments on the preparation of sulfonyl chloride and bromide are

  开发了在硝酸铵，HCl和HBr的水溶液以及氧气作为末端氧化剂的情况下，由硫醇对环境无害，无金属的磺酰氯和溴化物的合成方法。检查了各种取代的硫酚，苄基，脂族和杂芳族硫醇的反应性。硝酸铵用作氮氧化物（NO / NO 2），它们是氧化还原催化循环中的关键参与者。无需萃取即可分离出磺酰氯和溴化物，并在短硅胶垫上“过滤”。与传统的分离和纯化方法相比，大大减少了溶剂的使用。还展示了用于将硫醇转化为磺酰胺的“一锅法”方案。显示了制备磺酰氯和溴化物的放大实验。讨论了可能的反应途径。
• Base-controlled Fe(Pc)-catalyzed aerobic oxidation of thiols for the synthesis of S–S and S–P(O) bonds
  作者：Hai Huang、Jeffrey Ash、Jun Yong Kang

  DOI：10.1039/c8ob00908b

  日期：——

  disulfides has been developed under mild reaction conditions. In addition, an aerobic oxidative cross-dehydrogenative coupling (CDC) reaction of thiols with P(O)–H compounds (H-phosphonates and H-phosphine oxide) for the formation of S–P(O) bonds has been demonstrated under the Fe(Pc) catalysis system with a base additive. Control experiments revealed that the use of a base (DIPA) in this system controls

  在温和的反应条件下，已开发出Fe（Pc）催化的硫醇的好氧氧化反应以合成二硫化物。此外，在以下条件下，已证明了硫醇与P（O）-H化合物（H-膦酸酯和H-膦氧化物）的需氧氧化交叉脱氢偶联（CDC）反应可形成S-P（O）键。具有碱性添加剂的Fe（Pc）催化系统。对照实验表明，在该系统中使用碱（DIPA）控制形成硫代磷酸盐的合成途径。
• Dihydropyrancarboxamides and uses thereof
  申请人：——

  公开号：US20040059138A1

  公开（公告）日：2004-03-25

  The present invention provides novel dihydropyrancarboxamide compounds of formula (I): 1 and collections of these compounds, and provides methods for the synthesis of these compounds; wherein R 1 -R 6 are as defined herein. Additionally, the present invention provides pharmaceutical compositions and methods for treating disorders such as proliferative diseases, and cancer, to name a few.

  本发明提供了式（I）的新颖二氢吡喃羧酰胺化合物： 1 以及这些化合物的集合，并提供了合成这些化合物的方法；其中R 1 -R 6 如本文所定义。此外，本发明提供了用于治疗增殖性疾病和癌症等疾病的药物组合物和方法。

表征谱图